Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Mirum announced financial results for the quarter ended September 30, 2026.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Mirum announced financial results for the quarter ended September 30, 2026
- Corporate update released alongside quarterly results
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 net product sales $185.7M, up from $133.0M, with 2026 guidance raised to $715M-$720M
- LIVMARLI sales $133.4M, up 45% year over year, while Bile Acid Medicines sales reached $52.3M, up 28%
- ATEBRIOZ FDA approval and launch added a commercial product for FOP, with pediatric label expansion planned for H1 2027
- Positive Phase 3 results for LIVMARLI and brelovitug support planned regulatory submissions, subject to further data and FDA review
- Q3 net loss $40.8M versus $2.9M income, driven by operating expenses of $245.5M and $93.6M R&D spending excluding stock compensation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.